Clinical Trials List
2020-05-01 - 2024-12-31
Phase III
Terminated4
-
Trial Applicant
MEDPACE TAIWAN LIMITED
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Hong-Cheng Gan Division of Hematology & Oncology
- I-hung Shao Division of Hematology & Oncology
- Kai-Jie Yu Division of Hematology & Oncology
- Yung-Chang Lin Division of Hematology & Oncology
- Rita cheng Division of Hematology & Oncology
- PO-HUNG LIN Division of Hematology & Oncology
- See-Tong Pang Division of Hematology & Oncology
- 沈鼎文 Division of Radiology
- Wen-Cheng Chang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- CHUNG-HSIN CHEN Division of Urology
- Yu-Chieh Tsai Division of Hematology & Oncology
- - - Division of Urology
- JHE-CYUAN GUO Division of Hematology & Oncology
- Yeong-Shiau Pu Division of Urology
- - - Division of Urology
- FU-JEN HSUEH Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Ching-Chan Lin Division of Hematology & Oncology
- Yi-Huei Chang Division of Urology
- Su-Peng Yeh Division of General Internal Medicine
- Hsi-Chin Wu Division of Urology
- Chi-Ping Huang Division of Urology
- Po-Fan Hsieh Division of Urology
- Che-Hung Lin Division of Hematology & Oncology
- Han Chang Division of General Surgery
- Chi-Rei Yang Division of Urology
- Wei-Ching Lin Division of Radiology
- 陳冠亨 Division of Urology
- Po-Jen Hsiao Division of Urology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
26 participants
-
Global
676 participants
